<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00138034</url>
  </required_header>
  <id_info>
    <org_study_id>APRICOT-3</org_study_id>
    <secondary_id>2003B257</secondary_id>
    <nct_id>NCT00138034</nct_id>
  </id_info>
  <brief_title>APRICOT-3: Antithrombotics in the Prevention of Reocclusion In COronary Thrombolysis -3</brief_title>
  <official_title>A Multicenter Randomized Trial in the Prevention of Reocclusion Following Successful Thrombolysis for Suspected Acute Myocardial Infarction: An Invasive Versus a Conservative Strategy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heartcenter, University Medical Center St. Radboud</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Netherlands Heart Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Interuniversity Cardiology Institute of the Netherlands</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Heartcenter, University Medical Center St. Radboud</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Reocclusion of the infarct artery is observed in about 30% of patients within three months
      after successful thrombolysis for acute myocardial infarction (MI). Reocclusion is associated
      with an increased risk of death, reinfarction and the need for revascularization. Even in the
      absence of clinical reinfarction, reocclusion results in impaired left ventricular (LV)
      recovery, leaving patients at increased risk of developing heart failure in the long-term.
      Prevention of reocclusion is therefore warranted. In previous trials, severity of the infarct
      related stenosis was the only independent predictor of reocclusion. With a lack of clinical
      predictors of reocclusion, many cardiologists therefore empirically favor routine
      revascularization after successful thrombolysis.

      The APRICOT-3 will be the first randomized trial in the current era of improved angioplasty
      techniques to study the question of whether a routine invasive strategy after successful
      thrombolysis can reduce the incidence of reocclusion and subsequently improve clinical
      outcome and LV-function. After successful thrombolysis, patients will be randomized to either
      a routine invasive strategy or an ischemia-guided strategy. The investigators expect to
      demonstrate a lower reocclusion rate at the 6-month follow-up angiography (primary endpoint)
      and fewer associated events (death, reinfarction, revascularization, admissions for heart
      failure) in the routine invasive arm. In search of non-invasive parameters predictive of
      reocclusion, laboratory analysis of several coagulation and inflammatory markers will be
      performed. Finally, pooled analysis of all 3 APRICOT trials will focus on the identification
      of clinical predictors of reocclusion that can easily be obtained by history and physical
      examination.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Randomized controlled study of elective percutaneous coronary intervention (PCI) of an open
      culprit lesion after fibrinolysis for ST-elevation myocardial infarction (STEMI)
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2005</start_date>
  <completion_date type="Actual">February 2010</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>6-month Reocclusion</measure>
    <time_frame>6 months</time_frame>
    <description>Less than TIMI (Thrombolysis In Myocardial Infarction) -3 flow of the infarct related coronary artery assessed at follow-up angiography</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Composite of Death, Reinfarction, Stroke and Revascularization at the Time of Follow-up Angiography</measure>
    <time_frame>6 months</time_frame>
    <description>The occurence of any one of the above mentioned outcome measures. Only the first event per patient is counted.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">49</enrollment>
  <condition>Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Percutaneous coronary intervention (PCI)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Stenting of the culprit lesion of the infarct related artery and aspirin and clopidorgel for at least 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dual antiplatelet therapy</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Aspirin and clopidogrel for at least 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Percutaneous coronary intervention (PCI)</intervention_name>
    <description>PCI with bare metal stent placement of the culprit lesion the in the infarct related artery</description>
    <arm_group_label>Percutaneous coronary intervention (PCI)</arm_group_label>
    <arm_group_label>Dual antiplatelet therapy</arm_group_label>
    <other_name>bare metal stent placement</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  TIMI-3 in infarct-related artery with a stentable lesion with 72 hours of thrombolysis
             for ST-elevation myocardial infarction

        Exclusion Criteria:

          -  Use of oral anticoagulants.

          -  Known intolerance to aspirin or clopidogrel.

          -  Bypass graft as infarct-related artery.

          -  Previously dilated infarct related artery.

          -  Significant left main stenosis.

          -  Unidentifiable culprit stenosis.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Freek WA Verheugt, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radboud University Nijmegen Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Radboud University Nijmegen Medical Center</name>
      <address>
        <city>Nijmegen</city>
        <state>Gelderland</state>
        <zip>6500 HB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 29, 2005</study_first_submitted>
  <study_first_submitted_qc>August 29, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 30, 2005</study_first_posted>
  <results_first_submitted>February 20, 2012</results_first_submitted>
  <results_first_submitted_qc>March 29, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 19, 2012</results_first_posted>
  <last_update_submitted>April 25, 2012</last_update_submitted>
  <last_update_submitted_qc>April 25, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 30, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Heartcenter, University Medical Center St. Radboud</investigator_affiliation>
    <investigator_full_name>Prof. Dr. F.W.A. Verheugt</investigator_full_name>
    <investigator_title>Professor of Cardiology</investigator_title>
  </responsible_party>
  <keyword>Open infarct-related artery within 72 hours of thrombolysis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were included from 1 january 2005 until december 2009</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Percutaeous Coronary Intervention (PCI)</title>
          <description>Stenting of culprit lesion followed by dual antiplatelet therapy</description>
        </group>
        <group group_id="P2">
          <title>Conservative Treatment</title>
          <description>Conservative treatment of culprit lesion with dual antiplatelet therapy</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Percutaeous Coronary Intervention (PCI)</title>
          <description>Stenting of culprit lesion followed by dual antiplatelet therapy</description>
        </group>
        <group group_id="B2">
          <title>Conservative Treatment</title>
          <description>Conservative treatment of culprit lesion with dual antiplatelet therapy</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="26"/>
            <count group_id="B2" value="23"/>
            <count group_id="B3" value="49"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60" spread="12"/>
                    <measurement group_id="B2" value="59" spread="13"/>
                    <measurement group_id="B3" value="59" spread="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Netherlands</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Austria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>6-month Reocclusion</title>
        <description>Less than TIMI (Thrombolysis In Myocardial Infarction) -3 flow of the infarct related coronary artery assessed at follow-up angiography</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Percutaeous Coronary Intervention (PCI)</title>
            <description>Stenting of culprit lesion followed by dual antiplatelet therapy</description>
          </group>
          <group group_id="O2">
            <title>Conservative Treatment</title>
            <description>Conservative treatment of culprit lesion with dual antiplatelet therapy</description>
          </group>
        </group_list>
        <measure>
          <title>6-month Reocclusion</title>
          <description>Less than TIMI (Thrombolysis In Myocardial Infarction) -3 flow of the infarct related coronary artery assessed at follow-up angiography</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Composite of Death, Reinfarction, Stroke and Revascularization at the Time of Follow-up Angiography</title>
        <description>The occurence of any one of the above mentioned outcome measures. Only the first event per patient is counted.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Percutaeous Coronary Intervention (PCI)</title>
            <description>Stenting of culprit lesion followed by dual antiplatelet therapy</description>
          </group>
          <group group_id="O2">
            <title>Conservative Treatment</title>
            <description>Conservative treatment of culprit lesion with dual antiplatelet therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Composite of Death, Reinfarction, Stroke and Revascularization at the Time of Follow-up Angiography</title>
          <description>The occurence of any one of the above mentioned outcome measures. Only the first event per patient is counted.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Percutaeous Coronary Intervention (PCI)</title>
          <description>Stenting of culprit lesion followed by dual antiplatelet therapy</description>
        </group>
        <group group_id="E2">
          <title>Conservative Treatment</title>
          <description>Conservative treatment of culprit lesion with dual antiplatelet therapy</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>intracerebral bleeding</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Freek W.A. Verheugt
has to following potential conflict of interest:
received educational and research grants from Bayer Healthcare, Roche, Eli Lilly and Boehringer Ingelheim
received honoraria for consultancies from Daiichi-Sankyo, Eli Lilly, Merck, The Medicines Company and Bayer Healthcare</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Professor Doctor F.W.A. Verheugt</name_or_title>
      <organization>Radboud University Medical Center Nijmegen</organization>
      <phone>+31(0)24-3614533</phone>
      <email>f.verheugt@cardio.umcn.nl</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

